Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D O Calligaro

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
The British Journal of Psychiatry. Supplement|April 22, 1999
Olanzapine: a basic science updateF Bymaster, K W Perry, D L Nelson, et al.
The Journal of Clinical Psychiatry|January 1, 1997
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drugF P Bymaster, K Rasmussen, D O Calligaro, et al.
Arzneimittel-Forschung|March 1, 1991
General pharmacology of a new potent 5-hydroxytryptamine antagonistP D Williams, D O Calligaro, W E Colbert, et al.
Journal of Medicinal Chemistry|November 27, 1992
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacyW H Lunn, D D Schoepp, D O Calligaro, et al.
General Pharmacology|May 14, 1999
Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aortaB D Sawyer, F P Bymaster, D O Calligaro, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1996
Radioreceptor binding profile of the atypical antipsychotic olanzapineF P Bymaster, D O Calligaro, J F Falcone, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1992
Preclinical studies on LY237733, a potent and selective serotonergic antagonistM M Foreman, R W Fuller, D L Nelson, et al.
Schizophrenia Research|May 5, 1999
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitroF P Bymaster, D L Nelson, N W DeLapp, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994
Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivityM M Foreman, R W Fuller, K Rasmussen, et al.
Journal of Medicinal Chemistry|September 4, 1992
Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinonesL A McQuaid, E C Smith, K K South, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
The British Journal of Psychiatry. Supplement|April 22, 1999
Olanzapine: a basic science updateF Bymaster, K W Perry, D L Nelson, et al.
The Journal of Clinical Psychiatry|January 1, 1997
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drugF P Bymaster, K Rasmussen, D O Calligaro, et al.
Arzneimittel-Forschung|March 1, 1991
General pharmacology of a new potent 5-hydroxytryptamine antagonistP D Williams, D O Calligaro, W E Colbert, et al.
Journal of Medicinal Chemistry|November 27, 1992
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacyW H Lunn, D D Schoepp, D O Calligaro, et al.
General Pharmacology|May 14, 1999
Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aortaB D Sawyer, F P Bymaster, D O Calligaro, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1996
Radioreceptor binding profile of the atypical antipsychotic olanzapineF P Bymaster, D O Calligaro, J F Falcone, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1992
Preclinical studies on LY237733, a potent and selective serotonergic antagonistM M Foreman, R W Fuller, D L Nelson, et al.
Schizophrenia Research|May 5, 1999
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitroF P Bymaster, D L Nelson, N W DeLapp, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994
Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivityM M Foreman, R W Fuller, K Rasmussen, et al.
Journal of Medicinal Chemistry|September 4, 1992
Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinonesL A McQuaid, E C Smith, K K South, et al.
Pageof 5